Clinical Research Directory
Browse clinical research sites, groups, and studies.
Bimzelx (Bimekizumab) For The Treatment Of Adult Onset PRP
Sponsor: Mayo Clinic
Summary
The purpose of this study is to valuate the clinical efficacy of Bimzelx therapy in adults with Pityriasis Rubra Pilaris.
Official title: Bimzelx (Bimekizumab) For The Treatment Of Adult Onset Pityriasis Rubra Pilaris: A Single Arm, Open?Label, Exploratory Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
12
Start Date
2026-07-01
Completion Date
2027-12-01
Last Updated
2026-03-27
Healthy Volunteers
No
Conditions
Interventions
Bimekizumab
Subjects will receive subcutaneous injection of 320 mg at Weeks 0, 4, 8, 12, and 16, then every 8 weeks thereafter for 24 weeks. For patients weighing ≥ 120 kg, 320 mg every 4 weeks after Week 16, for 24 weeks.
Locations (1)
Mayo Clinic in Florida
Jacksonville, Florida, United States